Boryung Corporation (003850.KS)
KRW 10260.0
(-3.39%)
KRW 10260.0
(-3.39%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 40.2 Billion KRW | -4.04% |
| 2022 | 41.89 Billion KRW | -2.67% |
| 2021 | 43.04 Billion KRW | 60.28% |
| 2020 | 26.85 Billion KRW | -16.65% |
| 2019 | 32.22 Billion KRW | 58.67% |
| 2018 | 20.3 Billion KRW | -64.18% |
| 2017 | 56.69 Billion KRW | 909.93% |
| 2016 | 5.61 Billion KRW | -72.35% |
| 2015 | 20.3 Billion KRW | -5.97% |
| 2014 | 21.59 Billion KRW | 52.84% |
| 2013 | 14.12 Billion KRW | 50.27% |
| 2012 | 9.4 Billion KRW | 52.17% |
| 2011 | 6.17 Billion KRW | -54.74% |
| 2010 | 13.64 Billion KRW | 163.38% |
| 2009 | 5.18 Billion KRW | -0.45% |
| 2008 | 5.2 Billion KRW | -38.17% |
| 2007 | 8.41 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 23.64 Billion KRW | 1.03% |
| 2024 Q3 | 9.35 Billion KRW | -60.44% |
| 2024 Q1 | 23.4 Billion KRW | 318.19% |
| 2023 Q4 | 5.59 Billion KRW | -53.12% |
| 2023 Q1 | 11.35 Billion KRW | 278.67% |
| 2023 Q3 | 11.93 Billion KRW | 5.46% |
| 2023 FY | 40.2 Billion KRW | -4.04% |
| 2023 Q2 | 11.31 Billion KRW | -0.3% |
| 2022 Q2 | 15.09 Billion KRW | 35.01% |
| 2022 FY | 41.89 Billion KRW | -2.67% |
| 2022 Q4 | -6.35 Billion KRW | -128.94% |
| 2022 Q3 | 21.95 Billion KRW | 45.4% |
| 2022 Q1 | 11.18 Billion KRW | 96.99% |
| 2021 Q2 | -3.04 Billion KRW | -115.35% |
| 2021 Q1 | 19.84 Billion KRW | 345.42% |
| 2021 FY | 43.04 Billion KRW | 60.28% |
| 2021 Q3 | 20.56 Billion KRW | 775.07% |
| 2021 Q4 | 5.67 Billion KRW | -72.4% |
| 2020 Q1 | 8.33 Billion KRW | 55.96% |
| 2020 FY | 26.85 Billion KRW | -16.65% |
| 2020 Q3 | 7.63 Billion KRW | 18.71% |
| 2020 Q4 | 4.45 Billion KRW | -41.64% |
| 2020 Q2 | 6.43 Billion KRW | -22.83% |
| 2019 Q2 | 10.14 Billion KRW | 14.23% |
| 2019 FY | 32.22 Billion KRW | 58.67% |
| 2019 Q1 | 8.87 Billion KRW | 46.21% |
| 2019 Q3 | 7.85 Billion KRW | -22.49% |
| 2019 Q4 | 5.34 Billion KRW | -32.01% |
| 2018 Q4 | 6.07 Billion KRW | 26.61% |
| 2018 Q3 | 4.79 Billion KRW | 55.45% |
| 2018 FY | 20.3 Billion KRW | -64.18% |
| 2018 Q2 | 3.08 Billion KRW | -51.45% |
| 2018 Q1 | 6.35 Billion KRW | -87.39% |
| 2017 Q3 | 3.02 Billion KRW | 343.64% |
| 2017 Q4 | 50.39 Billion KRW | 1567.88% |
| 2017 FY | 56.69 Billion KRW | 909.93% |
| 2017 Q1 | 2.6 Billion KRW | 127.36% |
| 2017 Q2 | 681.07 Million KRW | -73.82% |
| 2016 FY | 5.61 Billion KRW | -72.35% |
| 2016 Q2 | 8.67 Billion KRW | 171.61% |
| 2016 Q3 | 3.24 Billion KRW | -62.59% |
| 2016 Q4 | -9.5 Billion KRW | -392.79% |
| 2016 Q1 | 3.19 Billion KRW | -22.35% |
| 2015 Q4 | 4.11 Billion KRW | -25.05% |
| 2015 Q2 | 5.33 Billion KRW | -0.58% |
| 2015 Q1 | 5.36 Billion KRW | -17.09% |
| 2015 FY | 20.3 Billion KRW | -5.97% |
| 2015 Q3 | 5.48 Billion KRW | 2.95% |
| 2014 Q1 | 5.87 Billion KRW | 24.26% |
| 2014 Q3 | 5.99 Billion KRW | 85.02% |
| 2014 Q4 | 6.46 Billion KRW | 7.84% |
| 2014 Q2 | 3.24 Billion KRW | -44.85% |
| 2014 FY | 21.59 Billion KRW | 52.84% |
| 2013 Q2 | 9.52 Billion KRW | 890.07% |
| 2013 Q4 | 4.73 Billion KRW | 533.05% |
| 2013 FY | 14.12 Billion KRW | 50.27% |
| 2013 Q1 | 962.09 Million KRW | -67.62% |
| 2013 Q3 | -1.09 Billion KRW | -111.47% |
| 2012 FY | 9.4 Billion KRW | 52.17% |
| 2012 Q1 | 2.06 Billion KRW | 1893.28% |
| 2012 Q4 | 2.97 Billion KRW | 40.76% |
| 2012 Q3 | 2.11 Billion KRW | -6.46% |
| 2012 Q2 | 2.25 Billion KRW | 9.41% |
| 2011 Q4 | 103.47 Million KRW | -87.72% |
| 2011 FY | 6.17 Billion KRW | -54.74% |
| 2011 Q3 | 842.88 Million KRW | -46.84% |
| 2011 Q2 | 1.58 Billion KRW | -59.31% |
| 2011 Q1 | 3.89 Billion KRW | 462.57% |
| 2010 Q2 | 6.27 Billion KRW | 104.61% |
| 2010 Q1 | 3.06 Billion KRW | 563.0% |
| 2010 FY | 13.64 Billion KRW | 163.38% |
| 2010 Q4 | -1.07 Billion KRW | -119.97% |
| 2010 Q3 | 5.38 Billion KRW | -14.24% |
| 2009 Q3 | 743.22 Million KRW | -77.24% |
| 2009 Q1 | 1.83 Billion KRW | 232.61% |
| 2009 Q2 | 3.26 Billion KRW | 77.79% |
| 2009 Q4 | -662.39 Million KRW | -189.12% |
| 2009 FY | 5.18 Billion KRW | -0.45% |
| 2008 Q4 | -1.38 Billion KRW | -234.51% |
| 2008 Q1 | 2.49 Billion KRW | 750.97% |
| 2008 Q2 | 3.06 Billion KRW | 22.74% |
| 2008 FY | 5.2 Billion KRW | -38.17% |
| 2008 Q3 | 1.02 Billion KRW | -66.4% |
| 2007 FY | 8.41 Billion KRW | 0.0% |
| 2007 Q2 | 2.37 Billion KRW | 16.51% |
| 2007 Q4 | 293.38 Million KRW | -92.11% |
| 2007 Q1 | 2.03 Billion KRW | 0.0% |
| 2007 Q3 | 3.71 Billion KRW | 56.68% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 659.857% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 30.672% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 167.469% |
| HANDOK Inc. | -28.79 Billion KRW | 239.605% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 577.741% |
| Yuhan Corporation | 93.5 Billion KRW | 57.007% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | -261.456% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 262.03% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 72.507% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | -1045.833% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 1703.997% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | 2038.503% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | 988.492% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | -80.017% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 659.857% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 291.982% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | -1021.926% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 133.992% |
| JW Holdings Corporation | 19.02 Billion KRW | -111.301% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 150.936% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 81.083% |
| JW Pharmaceutical Corporation | 37 Billion KRW | -8.638% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 170.131% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | -556.72% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | -2316.702% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | -703.294% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 659.857% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | -8.757% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 63.944% |
| JW Pharmaceutical Corporation | 37 Billion KRW | -8.638% |
| Yuhan Corporation | 93.5 Billion KRW | 57.007% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 347.406% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | 1137.346% |
| Suheung Co., Ltd. | 6.11 Billion KRW | -556.992% |
| JW Pharmaceutical Corporation | 37 Billion KRW | -8.638% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | -112.648% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 16.698% |
| CKD Bio Corp. | -24.19 Billion KRW | 266.179% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | -68.093% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | -46.521% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | -35.025% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 170.131% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 14.476% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 228.322% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 1703.997% |
| JW Lifescience Corporation | 28.14 Billion KRW | -42.847% |